New drug combo shows promise for rare, aggressive breast cancer
NCT ID NCT02623972
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This phase 2 study tests whether adding the drug eribulin to standard chemotherapy before surgery can improve outcomes for people with HER2-negative inflammatory breast cancer, a rare and aggressive type. The 22 participants receive eribulin first, followed by doxorubicin and cyclophosphamide, then surgery. The main goal is to see if the cancer disappears completely by the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eribulin (Halaven) followed by doxorubicin and cyclophosphamide
What this could lead to
If successful, this could lead to a more effective preoperative treatment for a rare and aggressive form of breast cancer.
What could go wrong
This is a small, early-phase trial with only 22 participants, so results may not apply to all patients. The treatment involves strong chemotherapy with known side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.